Antimicrobial drug pricing
Despite the constant development of antimicrobial resistance (AMR), few new antimicrobials are currently becoming available clinically. Alternative approaches, such as different mechanisms to fund their use, are being explored to encourage development of new antimicrobials.
Authors
- Christopher A. J. L. Little
- Tom Ashfield (ORCID: https://orcid.org/0000-0001-8082-3821)
- Beth Woods (ORCID: https://orcid.org/0000-0002-7669-9415)
- Ioannis Baltas (ORCID: https://orcid.org/0000-0002-8008-4835)
- Avaneesh Kumar Pandey (ORCID: https://orcid.org/0000-0001-8035-1713)
- Ashish Kumar Kakkar (ORCID: https://orcid.org/0000-0001-7768-7304)
- Nusrat Shafiq (ORCID: https://orcid.org/0000-0002-3270-4227)
- Samir Malhotra (ORCID: https://orcid.org/0000-0002-3963-820X)
- Michael Corley
- Harriet Tuson
- Zeshan Riaz
- Tom Rhodes
Institutions
- Pfizer (United Kingdom) (GB)
- British Society for Antimicrobial Chemotherapy (GB)
- University College London (GB)
- Post Graduate Institute of Medical Education and Research (IN)
- University of York (GB)
Publication Details
- Journal
- Communications Medicine
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1038/s43856-024-00594-9
- Citations
- 5
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 5.65
Funders
- Pfizer